Markets

Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer

Sep 8, 2026 · 07:35 AM ET· updated 1h ago

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER,

Why It Matters

A big, respected cancer hospital is now helping test BriaCell's new cancer medicine on more patients. This shows doctors think the treatment is worth studying carefully, which is a positive sign for the company.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BCTX3.59

+0.02 (+0.53%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.